Bowel Adenocarcinoma
Bowel adenocarcinoma is a cancer arising from the glandular cells that line the inner surface of the small or large intestine. The vast majority of bowel adenocarcinomas arise in the colon or rectum (colorectal cancer), which is one of the most common cancers overall. Small bowel adenocarcinoma is much less common but is an important entity in specific settings. Most colorectal cancers develop from precancerous polyps over years, making screening highly effective at prevention or early detection. Treatment depends on the cancer’s location, stage, and molecular characteristics and typically involves surgery, sometimes combined with chemotherapy, radiation, immunotherapy, or targeted therapies. Evaluation combines imaging (particularly CT), endoscopy (colonoscopy or, for small bowel, specialized techniques), and biopsy for tissue diagnosis.
What is it?
The bowel (intestine) is divided into the small intestine (which includes the duodenum, jejunum, and ileum) and the large intestine (which includes the cecum, colon, and rectum). The inner lining of the bowel contains glandular cells that produce mucus and other secretions and help absorb nutrients. Adenocarcinoma is a cancer that arises from these glandular cells. When adenocarcinoma occurs in the bowel, it most commonly develops in the colon or rectum (referred to together as colorectal cancer). Small bowel adenocarcinoma is much less common but is an important entity, particularly in certain patient populations.
Colorectal cancer typically develops through a slow progression from normal cells to precancerous polyps (adenomas) to cancer over many years. This slow progression is what makes screening so effective—the removal of precancerous polyps during colonoscopy can prevent cancer from developing, and early cancers are typically highly curable. Most colorectal cancers arise from adenomatous polyps (particularly certain types such as tubular, tubulovillous, and villous adenomas), and a smaller subset arises through a different pathway involving serrated polyps.
Several risk factors contribute to colorectal cancer risk. Age is the most important risk factor, with the majority of cases occurring in adults over 50, though rates of early-onset colorectal cancer (in adults under 50) have been increasing in recent decades and this has prompted lowering of the recommended screening age. Family history significantly increases risk, particularly with first-degree relatives affected at a young age. Inherited syndromes—including Lynch syndrome (hereditary nonpolyposis colorectal cancer, HNPCC), familial adenomatous polyposis (FAP), MUTYH-associated polyposis, and others—account for a small but important proportion of cases and require specific evaluation, screening, and family counseling. A personal history of colorectal polyps, colorectal cancer, or inflammatory bowel disease (ulcerative colitis or Crohn’s disease affecting the colon) increases risk. Lifestyle factors including obesity, physical inactivity, high consumption of red and processed meats, low intake of fruits and vegetables, heavy alcohol use, and smoking contribute to risk. Type 2 diabetes is also associated with increased risk.
Small bowel adenocarcinoma is much less common than colorectal cancer despite the small bowel being much longer than the large bowel. Reasons for the relative rarity are not entirely clear but likely include the rapid transit of contents, lower bacterial load, and other factors. Risk factors for small bowel adenocarcinoma include Crohn’s disease (particularly with long-standing small bowel involvement), celiac disease, hereditary syndromes (particularly Lynch syndrome and Peutz-Jeghers syndrome), and, in specific circumstances, other conditions. Small bowel adenocarcinoma most commonly arises in the duodenum, followed by the jejunum and ileum.
Symptoms of bowel adenocarcinoma depend on the location and stage of the tumor. Colorectal cancer symptoms may include changes in bowel habits (persistent diarrhea, constipation, or change in stool caliber), blood in the stool (which may be visible or detected only on stool testing), unexplained weight loss, fatigue (often from iron-deficiency anemia due to slow blood loss from the tumor), abdominal pain or cramping, and sensation of incomplete emptying after bowel movements. Right-sided colon cancers tend to bleed slowly and often present with fatigue and iron-deficiency anemia rather than obvious changes in bowel habits, while left-sided colon cancers more often cause changes in bowel habits, obstructive symptoms, or visible blood in the stool. Rectal cancers often cause bleeding, changes in stool caliber, and, in some patients, tenesmus (a sensation of needing to have a bowel movement without being able to).
Small bowel adenocarcinoma symptoms may be less specific and can include abdominal pain, weight loss, nausea and vomiting (particularly with obstruction), gastrointestinal bleeding, and, in some cases, jaundice when the tumor involves the duodenum near the ampulla of Vater. Because symptoms are often nonspecific and the small bowel is difficult to evaluate with standard endoscopy, small bowel adenocarcinoma is often diagnosed at a later stage than colorectal cancer.
Early cancers often cause few or no symptoms, which is why screening for colorectal cancer is highly recommended for adults meeting age and risk criteria. Screening approaches include colonoscopy (typically every 10 years starting at age 45 for average-risk adults in the United States, with earlier and more frequent screening for those with risk factors), stool-based tests (such as fecal immunochemical test [FIT] annually, or multi-target stool DNA test at defined intervals), CT colonography (in specific settings), and, in patients with hereditary syndromes, tailored surveillance protocols.
Diagnosis of colorectal cancer is typically made by colonoscopy, which allows direct visualization of the tumor and biopsy for tissue diagnosis. Colonoscopy also allows removal of polyps that are precancerous or amenable to endoscopic resection. For small bowel adenocarcinoma, evaluation may involve upper endoscopy (for duodenal tumors), capsule endoscopy, deep enteroscopy (with balloon-assisted techniques), CT enterography or MR enterography, and, in some cases, exploratory laparoscopy or laparotomy.
Staging is essential for treatment planning. For colorectal cancer, staging typically includes CT of the chest, abdomen, and pelvis to evaluate for spread to lymph nodes, liver, lungs, or other sites; MRI of the rectum for rectal cancer to evaluate local extent and lymph node involvement; endoscopic ultrasound for detailed rectal cancer evaluation in specific circumstances; PET/CT in some situations; and blood tests including complete blood count, liver and kidney function, and tumor markers such as CEA (carcinoembryonic antigen), which can be elevated in colorectal cancer and used as a marker for monitoring. Molecular testing of the tumor is increasingly important and guides treatment decisions—testing typically includes mismatch repair (MMR) protein status or microsatellite instability (MSI) status, RAS mutations (KRAS, NRAS), BRAF mutations, HER2 status, and other markers depending on the specific circumstances.
For patients with hereditary syndrome suspicion (based on young age at diagnosis, family history, multiple primary cancers, or specific tumor features), genetic counseling and, when appropriate, germline genetic testing are important. This has significant implications for both the individual patient’s care and for family members who may benefit from screening.
Important to Know
Management of bowel adenocarcinoma is highly individualized based on the specific location, stage, molecular characteristics, patient factors, and preferences. Care is best delivered by multidisciplinary oncology teams that include colorectal surgeons or surgical oncologists (for small bowel cancers), medical oncologists, radiation oncologists (particularly for rectal cancer), gastroenterologists, radiologists, pathologists, geneticists, and, when needed, other specialists including palliative care.
For localized colorectal cancer, surgery is the mainstay of curative treatment. The specific procedure depends on the tumor’s location. Colectomy (removal of the affected portion of the colon along with associated lymph nodes and blood supply) is performed for colon cancer, with the extent depending on the tumor location. Right hemicolectomy, left hemicolectomy, sigmoid colectomy, and total or subtotal colectomy are examples of specific approaches. Rectal cancer surgery may involve low anterior resection (removal of the rectum with reconnection of the colon to the remaining rectum or anus) or abdominoperineal resection (removal of the rectum and anus with a permanent colostomy), depending on the tumor location and other factors. Minimally invasive approaches (laparoscopic or robotic-assisted surgery) are commonly used and offer some advantages over open surgery in appropriate patients. For very early cancers, endoscopic resection may be appropriate in selected cases.
For rectal cancer, treatment often involves a multimodal approach that may include preoperative (neoadjuvant) chemotherapy and/or radiation therapy, surgery, and postoperative (adjuvant) chemotherapy, depending on the stage and characteristics. Total neoadjuvant therapy (TNT)—which delivers both chemotherapy and chemoradiation before surgery—has become increasingly used for locally advanced rectal cancer. For selected patients who have a complete response to neoadjuvant treatment, watch-and-wait approaches (nonoperative management with close surveillance) are increasingly considered in specialized centers.
For colon cancer that has spread to nearby lymph nodes (stage III), adjuvant chemotherapy after surgery is standard and has been shown to significantly improve outcomes. Regimens typically include combinations of fluoropyrimidines (5-fluorouracil or oral capecitabine) with oxaliplatin (such as FOLFOX or CAPOX regimens). Duration is typically 3 to 6 months depending on the specific situation, with growing evidence supporting shorter duration in appropriate lower-risk patients.
For metastatic (stage IV) colorectal cancer, treatment approaches have evolved significantly and include several components. Chemotherapy regimens (typically containing fluoropyrimidines, oxaliplatin, and/or irinotecan) form the backbone of treatment. Targeted therapies matched to molecular characteristics include EGFR-directed therapies (such as cetuximab or panitumumab, used only in RAS wild-type tumors), VEGF-directed therapies (such as bevacizumab), BRAF-directed therapies (for BRAF V600E-mutant tumors, often combined with EGFR-directed therapy), HER2-directed therapies (for HER2-amplified tumors), and others. Immunotherapy with immune checkpoint inhibitors has transformed treatment of tumors with mismatch repair deficiency or high microsatellite instability (MMRd/MSI-H), which occur in a subset of colorectal cancers—these tumors are highly responsive to immunotherapy, and it has moved to first-line treatment in metastatic settings and, increasingly, earlier disease. For patients with limited metastatic disease (particularly to the liver or lungs), surgical resection of metastases or other local treatments (such as ablation) can offer meaningful long-term outcomes in appropriately selected patients.
For small bowel adenocarcinoma, treatment principles broadly follow those for colorectal cancer, with surgical resection as the mainstay of curative treatment and chemotherapy in advanced or higher-risk disease. Because small bowel adenocarcinoma is less common, care at centers with experience in this less common cancer is often beneficial, and clinical trial participation is important.
For patients with hereditary syndromes (particularly Lynch syndrome and FAP), care includes:
– Coordinated evaluation and treatment of the primary cancer
– Genetic counseling and family screening
– Long-term surveillance for other cancers associated with the syndrome (such as colorectal, endometrial, urinary tract, and gastric cancers in Lynch syndrome; colon polyps and cancers in FAP)
– Consideration of preventive strategies (such as risk-reducing colectomy or gynecologic surgery in appropriate patients)
For advanced disease, palliative care is an important component of treatment and can be integrated alongside cancer-directed therapy at any stage. Palliative care can address pain, symptoms, quality of life, and end-of-life planning as needed.
Long-term follow-up after treatment for colorectal cancer is important because of the risk of recurrence. Standard surveillance typically includes clinical assessment, tumor markers (CEA), CT imaging, and colonoscopy at defined intervals. Surveillance schedules are individualized based on stage, treatment, and other factors, and are often intensive in the first several years after treatment.
For patients considering fertility preservation before treatment, coordination with reproductive medicine is important, particularly for younger patients receiving chemotherapy or pelvic radiation.
Nutritional support, mental health support, physical rehabilitation, and support for family and caregivers are important components of comprehensive cancer care.
Care during pregnancy in patients with colorectal cancer is complex and requires coordination with oncology, obstetrics, maternal-fetal medicine, and surgery. Treatment decisions balance the mother’s oncologic needs with fetal safety, and management is highly individualized.
Care is best coordinated by multidisciplinary oncology teams. Imaging, laboratory, pathology, and molecular findings are interpreted alongside the patient’s symptoms, examination, family history, and broader clinical context rather than in isolation.
Patient education plays an essential role. Understanding the diagnosis, the specific characteristics of the tumor including molecular features, the rationale for the recommended treatment plan, the importance of surveillance, the significance of hereditary syndromes when identified, treatment side effects, and warning signs of complications or recurrence all contribute to better outcomes.
Red flag symptoms include severe abdominal pain, symptoms of bowel obstruction (severe abdominal pain, distention, vomiting, inability to pass stool or gas), significant gastrointestinal bleeding (large amounts of visible blood, black tarry stools, or lightheadedness with bleeding), high fever with signs of severe infection, sudden severe pain (which may suggest perforation), signs of sepsis, severe difficulty breathing (which may suggest lung metastases or pulmonary embolism), new severe back pain with weakness, numbness, or bowel or bladder changes (which may indicate spinal cord compression from metastases), unintended significant weight loss, jaundice, or rapid clinical deterioration. These warrant prompt or urgent medical evaluation.